Location History:
- Osaka, JP (2011)
- Tokyo, JP (2005 - 2012)
- Kanagawa, JP (2009 - 2013)
Company Filing History:
7 out of 257 
6 out of 389 
3 out of 73 
Years Active: 2005-2013
Title: Innovations by Fumiaki Uehara in Neurodegenerative Disease Treatment
Introduction
Fumiaki Uehara is a notable inventor based in Tokyo, Japan, recognized for his significant contributions to the field of pharmaceuticals, particularly in developing treatments for neurodegenerative diseases. With a remarkable portfolio of 10 patents, his work focuses on innovative compounds that inhibit tau protein kinase 1 activity, which is crucial in addressing conditions like Alzheimer’s disease.
Latest Patents
Uehara's latest patents include two primary innovations:
1. **2-Substituted-6-Heterocyclic Pyrimidone Derivatives**: This compound is designed to serve as a tau protein kinase 1 inhibitor, identified by the formula (I) and its optically active isomers. The invention encompasses various substituents such as hydrogen, oxygen, halogens, and specific alkyl or aryl groups, which enhance its therapeutic applicability for treating diseases associated with tau protein kinase 1 anomalies, particularly neurodegenerative diseases like Alzheimer's.
2. **2-(Cyclic Amino)-Pyrimidone Derivatives**: This formation involves a similarly complex formula (I) targeting tau protein kinase 1 hyperactivity. The components include various atoms and groups, such as alkyl, halogens, and other substituents that can form rings. This compound aims to prevent or therapeutically manage diseases arising from tau protein kinase 1 hyperactivity, further reinforcing its utility in combating neurodegenerative disorders.
Career Highlights
Throughout his career, Uehara has made significant strides in pharmaceutical research and development. Notably, he has collaborated with prestigious organizations such as Mitsubishi Tanabe Pharma Corporation and Sanofi-Aventis. His dedication to innovation in the field has led to the successful patenting of numerous therapeutic compounds that hold promise for advancing treatment methodologies.
Collaborations
Uehara has collaborated with esteemed colleagues, including Kazutoshi Watanabe and Aya Shoda. These partnerships reflect his commitment to advancing research and maximizing the therapeutic potential of his inventions. Their collective expertise has undoubtedly contributed to the success of their developments, reinforcing teamwork in the scientific community.
Conclusion
Fumiaki Uehara's innovative patents and career achievements underscore his vital role in the progression of pharmaceutical treatments for neurodegenerative diseases. His contributions, especially in inhibiting tau protein kinase 1, illustrate the importance of continuous research and development in addressing complex medical challenges. As advancements in this field evolve, Uehara's work demonstrates the potential for impactful solutions that can significantly improve patients' quality of life.